Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ACACB | O00763 | 8/20 | 0.48 |
| ▸ | ACACA | Q13085 | 4/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353652 | 1.00 | KMT2A (0.71) | KMT2ASMN1; SMN2ACACBACACADRD2 | |
| SCHEMBL5006161 | 1.00 | KMT2A (0.71) | KMT2ASMN1; SMN2ACACBACACADRD2 | |
| SCHEMBL4653500 | 0.98 | KMT2A (0.69) | KMT2ASMN1; SMN2ACACBACACADRD2 | |
| SCHEMBL4653502 | 0.98 | KMT2A (0.69) | KMT2ASMN1; SMN2ACACBACACADRD2 | |
| SCHEMBL25036375 | 0.94 | KMT2A (0.64) | KMT2ASMN1; SMN2ACACBACACADRD2 | |
| SCHEMBL4354977 | 0.91 | KMT2A (0.60) | KMT2ASMN1; SMN2ACACBACACADRD2 | |
| SCHEMBL4346477 | 0.91 | KMT2A (0.60) | KMT2ASMN1; SMN2ACACBACACADRD2 | |
| SCHEMBL6641585 | 0.91 | KMT2A (0.60) | KMT2ASMN1; SMN2ACACBACACADRD2 | |
| SCHEMBL6641586 | 0.91 | KMT2A (0.60) | KMT2ASMN1; SMN2ACACBACACADRD2 | |
| Bicarbonate SCHEMBL1580718 | 0.90 | KMT2A (0.57) | KMT2ASMN1; SMN2ACACBACACADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 525 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113667706-B | Tranexamic acid-loaded cross-linked porous starch and preparation method thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-02-18 | — | — | CN | claimed |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2026098607-A1 | F-18 LABELED AQUEOUS PHARMACEUTICAL COMPOSITION TARGETING LIGAND OF FIBROBLAST ACTIVATION PROTEIN, AND PREPARATION METHOD THEREFOR | 天津恒瑞医药有限公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4711362-A1 | LIGAND TARGETING FIBROBLAST ACTIVATION PROTEIN | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-03-18 | — | — | EP | disclosed |
| CN-116916924-B | MALT1 modulators and uses thereof | 稀有生物科学股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4598908-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | Pfizer Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-0714299-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| EP-0641770-A1 | NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-03-08 | — | — | EP | disclosed |
| WO-1995002405-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| US-5166403-A | Liquid crystals | SHOWA DENKO K.K. (JP) | 1992-11-24 | — | — | US | disclosed |
| US-4954512-A | Anti-ulcer composition | Okamoto, Shosuke (JP) | 1990-09-04 | — | — | US | disclosed |
| US-4895842-A | Phenylalanine derivative and proteinase inhibitor | SHOSUKE OKAMOTO (JP) | 1990-01-23 | — | — | US | disclosed |
| US-4873253-A | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1989-10-10 | — | — | US | disclosed |
| EP-0317959-A2 | Anti-ulcer composition | Okamoto, Shosuke (JP) | 1989-05-31 | — | — | EP | disclosed |
| EP-0284632-A1 | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1988-10-05 | — | — | EP | disclosed |
| EP-0217286-A1 | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | KMT2A 1111/4885SMN1; SMN2 3689/4885ACACB 3205/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | KMT2A 1674/4885SMN1; SMN2 646/4885ACACB 1455/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | KMT2A 1046/4885SMN1; SMN2 3075/4885ACACB 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.